Evidence map›Paper›PMID 28341829›Full record

ArticleScientific reports2017

USP9X deubiquitylating enzyme maintains RAPTOR protein levels, mTORC1 signalling and proliferation in neural progenitors.

Caitlin R Bridges, Men-Chee Tan, Susitha Premarathne, Devathri Nanayakkara, Bernadette Bellette, Dusan Zencak, Deepti Domingo, Jozef Gecz, Mariyam Murtaza, Lachlan A Jolly and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Ubiquitin system mutations in neurological diseases.Trends in biochemical sciences · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. USP9x promotes CD8Acta biochimica et biophysica Sinica · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Caitlin R BridgesEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
Men-Chee TanEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
Susitha PremarathneEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
Devathri NanayakkaraEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
Bernadette BelletteEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
Dusan ZencakEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
Deepti DomingoSchool of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.
Jozef GeczSchool of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.ORCID 0000-0002-7884-6861
Mariyam MurtazaEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia.
Lachlan A JollyRobinson Institute, School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, South Australia, Australia. lachlan.jolly@adelaide.edu.au.
Stephen A WoodEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia. s.wood@griffith.edu.au.ORCID 0000-0002-2576-7457
Griffith University · AUThe University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

USP9X, is highly expressed in neural progenitors and, essential for neural development in mice. In humans, mutations in USP9X are associated with neurodevelopmental disorders. To understand USP9X's role in neural progenitors, we studied the effects of altering its expression in both the human neural progenitor cell line, ReNcell VM, as well as neural stem and progenitor cells derived from Nestin-cre conditionally deleted Usp9x mice. Decreasing USP9X resulted in ReNcell VM cells arresting in G0 cell cycle phase, with a concomitant decrease in mTORC1 signalling, a major regulator of G0/G1 cell cycle progression. Decreased mTORC1 signalling was also observed in Usp9x-null neurospheres and embryonic mouse brains. Further analyses revealed, (i) the canonical mTORC1 protein, RAPTOR, physically associates with Usp9x in embryonic brains, (ii) RAPTOR protein level is directly proportional to USP9X, in both loss- and gain-of-function experiments in cultured cells and, (iii) USP9X deubiquitlyating activity opposes the proteasomal degradation of RAPTOR. EdU incorporation assays confirmed Usp9x maintains the proliferation of neural progenitors similar to Raptor-null and rapamycin-treated neurospheres. Interestingly, loss of Usp9x increased the number of sphere-forming cells consistent with enhanced neural stem cell self-renewal. To our knowledge, USP9X is the first deubiquitylating enzyme shown to stabilize RAPTOR.

Indexed as

Cell Self RenewalAnimalsCell Cycle CheckpointsEndopeptidasesHEK293 CellsHumansMechanistic Target of Rapamycin Complex 1MiceNeural Stem CellsProteolysisRegulatory-Associated Protein of mTORSignal TransductionUbiquitin ThiolesteraseEndopeptidasesMechanistic Target of Rapamycin Complex 1Regulatory-Associated Protein of mTORRPTOR protein, humanRptor protein, mouseUbiquitin ThiolesteraseUSP9X protein, humanUsp9x protein, mouse

Identifiers

PMID28341829
PMCPMC5427856
OpenAlexW2597599079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.